cover
Contact Name
Darmadi Hariyanto
Contact Email
Darmadi Hariyanto
Phone
-
Journal Mail Official
jurnalpori@gmail.com
Editorial Address
-
Location
Kota adm. jakarta pusat,
Dki jakarta
INDONESIA
Radioterapi & Onkologi Indonesia
ISSN : 20869223     EISSN : -     DOI : -
Majalah Radioterapi & Onkologi Radiasi Indonesia (Journal of the Indonesian Radiation Oncology Society) dengan ISSN 2086-9223, satu-satunya majalah dalam bidang Onkologi Radiasi di Indonesia, merupakan majalah di bawah penerbit Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia (PORI). Majalah ini rutin diterbitkan sejak tahun 2010 dengan frekuensi terbitan 2 kali dalam setahun.
Arjuna Subject : -
Articles 99 Documents
Role of Radiation in Metachronous Multicentric Giant Cell Tumor of Bone: A Case Report Nana Supriana; David Andi Wijaya
Radioterapi & Onkologi Indonesia Vol 12, No 2 (2021): VOLUME 12 NO.2 JULY 2021
Publisher : Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia (PORI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32532/jori.v12i2.141

Abstract

Introduction: Giant cell tumor of the bone (GCTB) is a rare benign locally aggressive tumor. Surgical resection whenever feasible is treatment of choice for GCTB. Case Presentation: In this report the author will review a case of well locally controlled postoperative GCTB on left ilium bone after adjuvant radiation was delivered, with metachronous lesion on right calcaneus and distal tibia which appeared 9 years later.Conclusions: Radiation either in adjuvant setting or definitive in unresectable lesion could bring adequate local control.
Dosimetric Parameter Analysis of Stereotactic Radiosurgery on Vestibular Schwannoma with Intensity-Modulated Radiotherapy Step-and-Shoot, Volumetric-Modulated Arc Therapy and Helical Tomotherapy Soehartati A. Gondhowiardjo; Aurika Sinambela; Handoko Handoko; Arie Munandar; Wahyu Edy Wibowo; Sri Mutya Sekarutami; Angela Giselvania
Radioterapi & Onkologi Indonesia Vol 12, No 2 (2021): VOLUME 12 NO.2 JULY 2021
Publisher : Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia (PORI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32532/jori.v12i2.140

Abstract

Introduction: SRS is a non-invasive modality in management of vestibular schwannoma. There is limited study comparing dosimetric parameters between three techniques SRS in vestibular schwannoma cases, thus IMRT Step and Shoot (IMRT-SS), VMAT, and Helical Tomotherapy (HT). Aim: To compare the dosimetry parameters on SRS among IMRT-SS, VMAT, and HT techniques on Vestibular ScwhanomaMethod: Treatment planning with IMRT-SS, VMAT, and HT on eleven CT plan data for schwannoma vestibular cases. The marginal dose is 12 Gy with single fraction. Results: Mean tumor size was 8.23 cm + 5.08 cm3. No significant difference were found in the mean CI, GI, V100%, and V50% among three techniques. There was no significant difference in maximal dose to brainstem, ipsilateral cochlea, chiasma opticum, ipsilateral and contralateral optic nerve between the three techniques. There was significant difference of maximum dose on contralateral cochlea between IMRT-SS and VMAT techniques. The longest beam-on time was obtained with HT technique (1209,18 +390,20 second), followed by IMRT-SS technique (665,05 + 73,40 second), and the shortest was with VMAT technique (362,87 + 24,55 second). There was significant difference in mean MU and beam on time between three techniques. Conclusion: VMAT technique could be an option for SRS for vestibular schwannoma cases to provide conformity and gradient index as well as IMRT-SS and HT techniques, with better sparing to contralateral cochlea compared with IMRT-SS technique, and provides shorter beam-on time rather than IMRT-SS and HT.
Interpretation of Multilocular Ameloblastoma and Root Dilation of Teeth Azda Nurma Himammi; Bambang Tri Hartomo
Radioterapi & Onkologi Indonesia Vol 12, No 2 (2021): VOLUME 12 NO.2 JULY 2021
Publisher : Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia (PORI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32532/jori.v12i2.123

Abstract

Ameloblastoma is an odontogenic tumor composed of the epithelium of the teeth, and is a benign tumor that develops slowly and does not cause pain. In general, ameloblastoma is benign and clinically ameloblastoma is usually asymptomatic and does not cause changes in sensory nerve function. The indications for periapical radiographs include, among others, to detect apical infection or an inflammation, to know the assessment of periodontal status, to know the presence of trauma to the tooth or to the alveolar bone, to assess the morphology of the tooth root before extraction, during endodontic treatment, to evaluate preoperative and postoperative apical. evaluation of apical cysts and lesions in the alveolar bone and evaluating after implant placement. The radiological features of ameloblastoma that are most often found are multilocular lesions which are often described as soap bubbles if the lesions are large and honeycomb images when the lesions are small, while unicystic ameloblastomas are seen as well-defined lesions surrounded by unerupted dental corona. This radiograph is an important diagnostic support for various types of oral lesions especially those involving the alveolar bone. The diagnosis of ameloblastoma is often made based on radiographs. In this case there was an appearance of ameloblastoma at the tip of the alveolar bone of tooth 18 which is the most common odontogenic jaw tumor, this tumor develops from epithelial tissue and dental tissue in various stages of development.
Radiation Recall Phenomenon: A Literature Review Charity Kotambunan; Soehartati A. Gondhowiardjo
Radioterapi & Onkologi Indonesia Vol 12, No 2 (2021): VOLUME 12 NO.2 JULY 2021
Publisher : Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia (PORI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32532/jori.v12i2.134

Abstract

The radiation recall phenomenon is an inflammatory reaction on a previously irradiated area of the body that occurs due to exposure to triggering agents. In cancer settings, radiotherapy is often followed by chemotherapy or other systemic therapies, and this combination can trigger the radiation recall phenomenon. The triggering agents associated with this reaction are generally cytotoxic (e.g., chemotherapy); however, other agents usage has been widely reported. This reaction manifested in various areas of the body, with the skin being the most predilection site. There is no absolute range of radiation doses associated with this reaction. The interaction among radiotherapy components, triggering agents, and time of the agent’s initiation influences the risk and onset of this phenomenon. Although known for a long time, the mechanism is ambiguous. A series of hypothetical theories are described, including their relation to stem cell function and sensitivity, vascular damage, and drug hypersensitivity reactions. Management of this reaction may include modifying triggering agents, administration of steroids, and other symptomatic therapies. In severe cases, surgical intervention can be performed. Comprehensive observational or even experimental databases are needed for this phenomenon to be entirely understood. 
Annual Scientific Meeting of Indonesian Radiation Oncology Society 2021 Agustinus Darmadi Hariyanto
Radioterapi & Onkologi Indonesia Vol 13, No 1 (2022): Volume 13 No.1 January 2022
Publisher : Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia (PORI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32532/jori.v13i1.156

Abstract

Combination of Adoptive Cell Therapy and Radiotherapy in Cancer Management Vito Filbert Jayalie; Endang Nuryadi
Radioterapi & Onkologi Indonesia Vol 13, No 1 (2022): Volume 13 No.1 January 2022
Publisher : Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia (PORI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32532/jori.v13i1.137

Abstract

Cancer remains a healthcare burden in the world, with the increasing cases and deaths. Adoptive cell therapy (ACT) is one of the immunotherapies which modifies immune system to recognize cancer cells, which is then transfused to induce antitumoral responses in the human body. ACT works by using cancer-specific immune cells, especially Natural Killer and T cells in the form of tumor-infiltrating lymphocytes, T-cell receptor or chimeric antigen receptor. As the combination therapy with radiotherapy, radiation is able to induce tumor-associated antigen (TAA) and major histocompatibility complex (MHC) class I expression, which leads to increased immune cells around the tumor. As the result, transferred ACT to the body may be able to proliferate and perform its function well. Moreover, radiotherapy is able to downregulate regulatory T cells and myeloid-derived suppressor cells which can inhibit the role of the immune system in attacking cancer. Clinically, studies combining radiation and ACT in cancer care are limited to several types of cancer, such as metastatic melanoma, nasopharyngeal cancer, lymphoma and non-small cell lung cancer. Radiotherapy is able to increase therapeutic efficacy, especially as a bridging therapy before ACT. Nevertheless, further trials to know the potency of combining ACT and radiotherapy in other types of cancer, especially in earlier stages are needed.
Irradiation on Extramedullary Plasmacytoma of Vulva : A case report Tirawan Sutedja; Nana Supriana; Angela Giselvania; Henry Kodrat
Radioterapi & Onkologi Indonesia Vol 13, No 1 (2022): Volume 13 No.1 January 2022
Publisher : Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia (PORI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32532/jori.v13i1.131

Abstract

Plasma cell neoplasm is a clonal plasma cell malignancy which is the result of B cell differentiation with special characteristics the presence of immunoglobulin secretion. The clinical presentation varies from monoclonal gammopathy to plasma cell leukemia. Only five to six percent of plasma cell neoplasms manifest as plasmacytoma.Solitary extramedullary plasmacytoma (EMP) in the vulva region is a rare case. The current study presents a recurrence case of EMP in left labia minora-vulva in 61-years-old patients who have undergone surgery with a complete response. Radiotherapy was given with a total dose of External Beam Radiotherapy (EBRT) 50.4 Gy and continued with brachytherapy cylinder intravagina five Gy in three fractions. Six months after complete radiation, there was no recurrence, metastasis or progression at follow-up.  
Role of Radiotherapy in Gestational Trophoblastic Neoplasia: A Case Report Arie Munandar; Viona Viona
Radioterapi & Onkologi Indonesia Vol 13, No 1 (2022): Volume 13 No.1 January 2022
Publisher : Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia (PORI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32532/jori.v13i1.143

Abstract

Gestational trophoblastic neoplasia (GTN) is a placental tissues malignancy that is prone to massive bleeding. Multimodality treatment is often needed to treat GTN, such as surgery and radiotherapy. Radiotherapy has a palliative role in case of hemorrhage and/or intracranial metastases.Radiotherapy is effective in controlling bleeding by destructing malignant blood vessels by inducing endothelial damage and increasing signal transduction pathway leading to apoptosis and increasing adhesion of thrombocytes to vascular endothelia resulting fibrosis. No dose and fractionation schemes are proven more effective than others, but longer fractions scheme (>5 fractions) and BED10 > 39 Gy show no additional benefit in hemostatic control or in reduction of re-bleeding rate.Brain metastatic lesions are prone to bleeding that might need craniotomy for blood evacuation or brain decompression. WBRT can be given concurrently with chemotherapy in brain metastatic GTN cases. Higher WBRT total dose (>22 Gy) associated with higher 5-year local control rates.
Patients Outcome with Brain Oligometastases Treated with the SIB-IMRT Technique: Dr. Kariadi General Hospital Experience Christina Hari Nawangsih; Harman Juniardi; Dion Firli; Sigit Wirawan; Sri Rahayu Subandini; Diaza Okadimar Ariyanto
Radioterapi & Onkologi Indonesia Vol 13, No 1 (2022): Volume 13 No.1 January 2022
Publisher : Perhimpunan Dokter Spesialis Onkologi Radiasi Indonesia (PORI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.32532/jori.v13i1.142

Abstract

Brain metastases are often considered as the end of life in oncologic diseases. Previously, a standalone Whole Brain Radiotherapy (WBRT) had been the standard of care in the case of single or multiple lesions. Currently, Simultaneous Integrated Boost - Intensity Modulated Radiotherapy (SIB-IMRT) permits the delivery of simultaneous doses within a single therapy to the whole brain and the local lesion, therefore shifting the care expectation from palliative towards curative. This study summarizes the outcome in cancer patients with brain oligometastases that were treated with the SIB-IMRT technique. Between April 2020 and April 2021, a total of 29 brain oligometastases patients were treated with the SIB-IMRT technique at Dr. Kariadi General Hospital. Twenty patients completed treatment with a whole-brain dose of 37.5 Gy and tumor dose of 45 Gy, both in 15 fractions. Among fifteen who were successfully followed-up, six at the 6th-month follow-up, complete data of four patients were included. All four patients improved clinically. Evaluation from imaging revealed mass reductions in two patients, while one patient’s metastases were progressing, and the other one showed no changes. Additionally, no patients demonstrated cerebral necrosis as a late side effect.

Page 10 of 10 | Total Record : 99